-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

4230 Validation of ELN 2022 Risk Classification in Patients Diagnosed with AML Undergoing Allogeneic Hematopoietic Cell Transplantation

Program: Oral and Poster Abstracts
Session: 613. Acute Myeloid Leukemias: Clinical and Epidemiological: Poster III
Hematology Disease Topics & Pathways:
Acute Myeloid Malignancies, AML, Clinical Practice (Health Services and Quality), Diseases, Myeloid Malignancies
Monday, December 11, 2023, 6:00 PM-8:00 PM

Carlos Jimenez-Vicente, MD1*, Paola Charry, MD2*, Maria Suarez-Lledo, MD, PhD3*, Beatriz Merchán Muñoz, MD2*, Sandra Castaño-Díez, MD1*, Amanda Isabel Perez-Valencia4*, Alexandra Martínez-Roca, MD4*, Francesca Guijarro, MD5*, Mònica López-Guerra6*, Albert Cortés-Bullich, MD4*, Daniel Esteban3*, Ares Guardia-Torrelles4*, Ines Zugasti4*, Daniel Munárriz, MD3*, Laura Rosiñol, MD, PhD2*, Alvaro Urbano-Ispizua Sr., MD2, Francesc Fernández-Avilés, MD3*, Carmen Martinez, MD, PhD3*, Marina Díaz-Beyá, MD, PhD1*, Montserrat Rovira, MD, PhD3*, Maria Queralt Salas2* and Jordi Esteve, MD, PhD1

1Hematology Department, Hospital Clínic Barcelona, Barcelona, Spain
2Hematopoietic Cell Transplantation Unit, Hospital Clínic de Barcelona, ICHMO, Barcelona, Spain
3Hospital Clínic de Barcelona, Barcelona, Spain
4Hematology Department, Hospital Clinic de Barcelona, ICMHO, Barcelona, Spain
5Hematopathology Unit, Pathology Department, Hospital Clínic de Barcelona, Barcelona, Spain
6Hematopathology Section, Pathology Department, Hospital Clínic Barcelona, Barcelona, Spain


In 2022, the European LeukemiaNet (ELN) updated their guidelines (Döhner H et al., Blood 2022) for risk allocation of patients with acute myeloid leukemia (AML) based on essential genetic features at diagnosis as defined in the newest classifications (Arber D et al., Blood 2022, Khoury JD et al., Leukemia 2022).


Retrospective analysis of the 147 consecutive patients diagnosed with AML and available genetic information who underwent alloHCT in a complete morphological response (CR) between 2011 and 2021 in a single institution (HCB). Data was collected retrospectively and updated in July 2023. G-banding karyotype, FISH, qualitative and quantitative PCR and targeted Next Generation Sequencing were assessed at diagnosis to classify patients according to ELN 2022 risk classification. Our primary goal was to validate the ELN 2022 risk classification in patients undergoing alloHCT analyzing overall survival (OS). Secondary objectives were analyzing leukemia-free survival (LFS), 24-month cumulative incidence of relapse (CIR) and in the different molecular subgroups within the ELN2022 risk groups.


The main patient, disease-related and transplant characteristics are displayed in Figure 1. Overall, the median age was 52 years (range 18-70), 53.7% of the patients males, with 88% of the patients undergoing alloHCT in CR1. Twenty-two patients could not be classified through NGS assessment between 2011 and 2016 and included in the intermediate risk category due to normal karyotype and wildtype recurrent abnormalities measured by PCR. Patients in the adverse-risk group were older (p <0.001) and underwent alloHCT less often with undetectable measurable residual disease (p = 0.006). Moreover, patients in the favorable or intermediate risk group underwent alloHCT more often in CR2 or CR3 (p = 0.02). In addition, alloHCT characteristics were similar for all the patients included.

With a 67-month median follow-up for LFS (95CI: 55-76), the median OS and LFS in patients classified into the favorable and intermediate risk groups were not reached (5-year OS and LFS rate in favorable risk group: 81% (95CI: 73-89) and 72% (95CI: 63-81). 5-year OS and LFS rate in intermediate risk group: 62% (95CI: 56-68) and 64% (95CI: 58-70). Patients included in the adverse risk group had an OS and LFS of 23.7 months (15.3-NR, p <0.001 between intermediate and adverse risk. Figure 1B) and 15.2 months (5.79-NR, p=0.015) respectively, with a significant lower 5-year OS rate (40%, 95CI: 34-46), LFS rate (38%, 95CI: 32-44) and a higher CIR (18% in the favorable risk group (95%CI: 11-26) vs. 20% in the intermediate risk group (95%CI: 18-23) vs. 40% in the adverse risk group (95%CI: 38-44), p = 0.024).

Based on these results, a subanalysis was conducted in the patients classified into the adverse group. Those patients diagnosed with complex karyotype, inv(3), t(3;3), del(17p) and/or TP53 mutated were reassessed into a new risk category group called: Adverse-Plus (AdvP). No different baseline characteristics between the AdvP patients and the other subgroups were found. AdvP patients presented a shorter OS (NR in the rest of subgroups vs. 8.73 months in AdvP, p < 0.001 for AdvP vs. adverse risk. Figure 1C), LFS (NR in the rest of subgroups vs. 5.2 months, p < 0.001), and a higher CIR (62.5% in the AdvP group, p <0.001 between adverse risk and AdvP). Interestingly, using this four-group classification including AdvP, the other risk groups presented similar OS, LFS, and CIR without statistical differences in between them


ELN2022 risk classification discriminates properly accurate in patients undergoing alloHCT. Reclassifying AML adverse risk patients diagnosed with complex karyotype, inv(3), t(3;3), del(17p) and/or TP53 mutated in a different subgroup should be considered due to a much worse prognosis after alloHCT, although it remains mandatory in first complete response.

Disclosures: Jimenez-Vicente: Abbvie: Other: Speaker, Travel Grants; Pfizer: Other: Travel Grants. Martínez-Roca: Gilead: Other: Travel grants; Janssen: Other: travel grants; Takeda: Honoraria, Other: travel grants; Roche: Honoraria, Other: travel grants; Kite: Honoraria, Other: travel grants; Abbvie: Honoraria, Other: travel grants; BMS: Honoraria, Other: travel grants. Rosiñol: Bristol Myers Squibb/Celgene: Other: Honoraria for lectures; Janssen: Other: Honoraria for lectures; Amgen: Other: Honoraria for lectures; Sanofi: Other: Honoraria for lectures; Takeda: Other: Honoraria for lectures; GlaxoSmithKline: Other: Honoraria for lectures. Díaz-Beyá: Bristol Myers Squibb: Consultancy, Honoraria; Abbvie: Consultancy, Honoraria; Astellas: Consultancy, Honoraria; Jazz Pharma: Consultancy, Honoraria; Takeda: Consultancy, Honoraria; Novartis: Consultancy, Honoraria. Esteve: Jazz Pharmaceuticals: Consultancy, Research Funding; Gilead: Consultancy; Astellas: Consultancy; Abbvie: Consultancy; Kronos Bio: Research Funding; Pfizer: Research Funding.

*signifies non-member of ASH